|
Interagency Coordinating Committee for Newborn Screening
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, FDA, HRSA
|
NICHD
|
This committee makes recommendations for screening certain disorders, developing a system to adjudicate newborn screening expansion, and assist states in implementing programs to test for the recommended conditions.
|
|
Interagency Coordinating Committee on Fetal Alcohol Spectrum Disorders (ICCFASD)
|
Committee, Work group, Advisory group, or Task Force
|
ACF, ACL, ASPE, ASPR, ATSDR, CDC, CMS, HRSA, IHS, SAMHSA
|
NIAAA, NIMH, NIDA, NICHD
|
The Interagency Coordinating Committee on Fetal Alcohol Spectrum Disorders (ICCFASD) was created in October 1996 in response to recommendations of an expert committee of the Institute of Medicine that the National Institute on Alcohol Abuse and Alcoholism (NIAAA) chair an effort to coordinate Federal activities on Fetal Alcohol Syndrome (FAS) and other disorders associated with prenatal alcohol exposure. ICCFASD works to improve communication, cooperation, and collaboration among disciplines and federal agencies that address issues of health, education, developmental disability, research, justice, and social services relevant to FASD and related disorders caused by prenatal alcohol exposure. The ICCFASD meets twice a year and arranges special panels and working groups.
|
|
Interagency Coordinating Committee on Human Growth Hormone and Creutzfeldt - Jakob disease
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NIDDK, NICHD, NINDS
|
The Public Health Service Interagency Coordinating Committee on Human Growth Hormone (hGH) and Creutzfeldt-Jakob Disease (CJD) was established in 1985 by the Assistant Secretary for Health, the Department of Health and Human Services (HHS) to review information relevant to patients who received pituitary-derived hGH that was distributed through the NIH-funded National Hormone and Pituitary Program (NHPP). The Committee analyzes this information to determine the extent of the problem of transmission of CJD (a rare, incurable brain disease) through contaminated pituitary hGH, and to inform physicians and patients who received pituitary hGH about the health risks associated with pituitary hGH. Although NHPP’s distribution of hGH ceased when its potential to transmit CJD was discovered in 1985—and today, recombinant growth hormone that is not susceptible to CJD contamination is exclusively used for treatment—the Committee continues to maintain oversight of this issue because CJD may take years or decades to develop. The Committee includes representatives from the National Institutes of Health (NIH), the Food and Drug Administration (FDA), and the Centers for Disease Control and Prevention (CDC), and is chaired by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Director.
|
|
Interagency Coordinating Committee on the Prevention of Underage Drinking (ICCPUD)
|
Committee, Work group, Advisory group, or Task Force
|
ACF, CDC, IHS, OS, SAMHSA, OASH
|
NIDA, NIAAA
|
The Consolidated Appropriations Act of 2004 directed the Secretary of Health and Human Services (HHS) to establish the Interagency Coordinating Committee on the Prevention of Underage Drinking (ICCPUD) and to issue an annual report summarizing all Federal agency activities related to preventing underage alcohol use. HHS made ICCPUD a standing committee to provide ongoing, high-level leadership on this issue and to serve as a mechanism for coordinating Federal efforts aimed at preventing and reducing underage drinking. The Substance Abuse and Mental Health Services Administration (SAMHSA) serves as the lead ICCPUD agency.
|
|
Interagency Coordinating Committee on the Validation of Alternative Toxicological Methods (ICCVAM)
|
Committee, Work group, Advisory group, or Task Force
|
ATSDR, FDA, CDC
|
NIEHS, NCI, OD, NLM
|
Interagency committee of the federal government with representatives from 17 research and regulatory agencies that require, use, generate, or disseminate toxicological and safety testing information.
|
|
Interagency Elder Justice Working Group (EJWG)
|
Committee, Work group, Advisory group, or Task Force
|
ACL
|
NIA
|
The Elder Justice Interagency Working Group brings together federal officials responsible for carrying out elder justice activities, including elder abuse prevention, research, grant and program funding, and prosecution. Since 2001, members have met informally and on a regular basis to discuss emerging issues, promising practices, and ways to coordinate their efforts. Guest speakers have addressed a range of topics, including adult protective services, guardianship, and predatory lending.
|
|
Interagency Filovirus Team
|
Committee, Work group, Advisory group, or Task Force
|
ASPR
|
NIAID
|
Coordination across USG agencies of filovirus MCM activities
|
|
Interagency Group for Development of Lung Infection Models for P. aeruginosa and A.baumannii
|
Committee, Work group, Advisory group, or Task Force
|
BARDA, CDC, FDA
|
NIAID
|
This interagency working group meets quarterly to discuss the development of various lung infection animal models.
|
|
Interagency Group on Alzheimers Disease and Related Dementias for implementation of the National Alzheimers Project Act
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, FDA, HRSA, AoA, ASPE, ACF, IHS, OASH, SAMHSA
|
NIA
|
This interagency group was established by Department of Health and Human Services (HHS) in response to the Congressional directive to address Alzheimer disease. The group works to carry out the National Alzheimer’s Project Act’s charges to coordinate research and services across agencies, accelerate the development of AD/ADRD treatments, improve early diagnosis and coordination of care, reduce ethnic and racial disparities in rates of AD/ADRD, and coordinate with international efforts to fight these conditions.
|
|
Interagency Group on SARS-CoV-2 Evolution and Vaccine Cadence
|
Committee, Work group, Advisory group, or Task Force
|
ACF, ACL, AHRQ, ATSDR, CDC, CMS, FDA, HRSA, HIS, SAMHSA
|
NIAID
|
An interagency group convened to monitor SARS-CoV-2 evolution and advise on appropriate timing of vaccine and booster delivery.
|